We have targeted a K-ras allele in mouse embryonic stem (ES) cells to express a K-Ras V12 oncoprotein along with a marker protein (␤-geo) from a single bicistronic transcript. Expression of this oncogenic allele requires removal of a knocked in STOP transcriptional cassette by Cre recombinase. Primary mouse embryonic fibroblasts expressing this K-ras V12 allele do not undergo proliferative senescence and proliferate as immortal cells. In mice, expression of K-ras V12 throughout the body fails to induce unscheduled proliferation or other growth abnormalities for up to eight months. Only a percentage of K-ras V12 -expressing lung bronchiolo-alveolar cells undergo malignant transformation leading to the formation of multiple adenomas and adenocarcinomas. These results indicate that neoplastic growth induced by an endogenous K-ras oncogene depends upon cellular context.
Introduction
breast tumors (Bos, 1989) . The molecular bases for these variations are unknown. Moreover, its relative contribution to tumor Ras genes are some of the most widely studied cancer-related development is still obscure. Whereas in colon adenocarcinogenes due to their frequent activation in human tumors. These mas activation of K-ras oncogenes is an early but not an initiating prototypic small GTPases act as molecular switches that transevent, in other tumors, activation of K-ras oncogenes can be a fer information from the membrane to the nucleus. Some of their late event, sometimes associated with invasive or metastatic upstream activators include receptor and nonreceptor tyrosine processes (Bos, 1989) . protein kinases and, to a lesser extent, G protein-coupled recep-Unveiling the precise role of ras oncogenes in the developtors. Downstream, Ras proteins interact with multiple effector ment of human cancer is hindered by the sporadic nature of pathways. The best studied are those involved in mitogenic their activation and by the fact that tumors grow undetected for several years. The possibility to manipulate the mouse ge-signaling, the Raf/Mek/Erk pathway, and in survival, the phosphoinositol-3 kinase (PI3K)/Pdk/Akt pathway. The structure of nome has opened new opportunities to develop tumor models that recapitulate more closely those events responsible for the Ras proteins, both alone and associated with some of their downstream effectors, has been resolved, thus opening new human disease (Fisher et al., 2001; Jackson et al., 2001; Johnson et al., 2001; Meuwissen et al., 2001) . In this study, we opportunities for rational drug discovery (Downward, 2003; Vetter and Wittinghofer, 2001) .
describe gene-targeted mice in which expression of an endogenous K-ras oncogene, engineered by a knockin strategy, can Among ras oncogenes, K-ras is the most frequently activated in human tumors. However, its incidence varies widely.
be activated with synthetic steroids at any time and in any tissue. More importantly, expression of this oncogene can be Whereas K-ras oncogenes are found in almost 90% of pancreatic cancers, they are present in 50% of colon and 25% of monitored by coexpression of a bicistronic color marker. These mice have allowed us to illustrate that wide expression of an lung adenocarcinomas and basically absent from prostate and S I G N I F I C A N C E Gene-targeted mice described here allow us to monitor the fate of cells expressing an endogenous K-ras oncogene in somatic cells. Unexpectedly, most K-ras oncogene-expressing cells remain normal for long periods of time (up to eight months), including stem cells that retain their capacity to proliferate and differentiate to form hair follicles in the dermis or intestinal crypts. Only lung bronchiolo-alveolar cells acquire hyperproliferative properties and progress into malignant adenocarcinomas. These observations establish the experimental bases to identify those pathways that convey resistance or permissiveness to K-ras transformation within a physiological context. In addition, this work illustrates that an endogenous K-ras oncogene, when expressed at physiological levels, does not induce senescence due to oncogenic stress in mouse embryonic fibroblasts (MEFs). Instead, expression of the endogenous K-ras oncogene overrides proliferative senescence, a characteristic of immortal cells.
Figure 1. Gene targeting strategy
A: Homologous recombination at the 3Ј region of the K-ras locus. K-ras 4B exon: Black, coding sequences; white, noncoding sequences; dark gray, polyadenylation sequences. Light gray, IRES-␤-geo cassette. The location of the probe used in the Southern blot analysis is indicated. Representative restriction enzyme cleavage sites are indicated (H, HindIII; X, XbaI; S, SalI). B: Southern blot analysis of DNA isolated from (WT) wild-type and (HR) clones carrying the expected homologous recombination event after digestion with HindIII. The size of the wild-type (6.5 kbp) and targeted (10.5 kbp) alleles is indicated. C: Homologous recombination at the 5Ј region of the K-ras locus. White box, K-ras noncoding exon 0; black box, K-ras coding exon 1; Hyg, PGK-Hygromycin cassette; STOP, transcriptional inhibitory sequences; triangle, loxP sites; *, oncogenic mutation in codon 12. The position of the probe used in the Southern blot analysis is indicated. Representative restriction enzyme cleavage sites are indicated (X, XbaI; E, EcoRI; V, EcoRV; N, NotI). D: Southern blot analysis of DNA isolated from wild-type (WT) and clones (HR) carrying the expected homologous recombination event after digestion with XbaI. The size of the wild-type (5 kbp) and targeted (3.5 kbp) alleles is indicated.
endogenous K-ras oncogene has no consequences in most first exon with sequences carrying a mutant codon 12 encoding tissues and/or cell types, thus indicating that tumor developa valine residue, a mutation frequently found in human tumors ment is highly dependent on cellular context. Moreover, charac- (Bos, 1989) . In this recombination event, we also inserted within terization of mouse embryonic fibroblasts (MEFs) derived from the first intron transcriptional STOP sequences (Lakso et al., these mice reveals that expression of a K-ras oncogene at physi-1992) and a PGK-Hygro cassette flanked by loxP sites (Figure ological levels induces cellular immortalization instead of senes-1C). Seven out of 96 hygromycin-resistant clones tested (7%) cence (Serrano et al., 1997) .
displayed the expected recombination event ( Figure 1D ). Targeted ES cells carrying the two recombination events Results within the same K-ras allele (about 50% of the clones) were identified by their ability to express the ␤-geo marker only upon transfection with Cre recombinase. These cells expressed the Targeting strategy We have targeted mouse embryonic stem (ES) cells to generate targeted K-ras mRNA as determined by RT-PCR analysis followed by digestion with a diagnostic SfcI restriction endonucle-an oncogenic K-ras allele whose expression can be induced and monitored in vivo. To this end, we introduced by homologous ase as described in Figure 2 . Selected clones were submitted to cytogenetic analysis and those that exhibited a normal karyo-recombination an IRES-␤-geo cassette within the 3Ј untranslated region of a K-ras allele (Friedrich and Soriano, 1991) (Figure type (MCG537 and MCG758) were used to generate chimeric mice by microinjection into C57BL/6 blastocysts. Chimeric male 1A). The internal ribosomal entry site (IRES) allows bicistronic translation of ␤-geo sequences from a transcript driven by the mice were backcrossed to C57BL/6 females and germline transmission of the targeted allele scored by Southern blot analysis endogenous K-ras promoter (Mountford et al., 1994) . G418 resistant clones were submitted to Southern blot analysis to iden-of tail DNA from the agouti offspring. Heterozygous K-ras ϩ/V12 mice were born at the expected Mendelian ratios. These animals tify those that had undergone the expected recombination event ( Figure 1B ). We obtained a high percentage of homologous do not show obvious abnormalities. X-Gal analysis of embryos and tissues derived from heterozygous K-ras ϩ/V12 mice does recombinant clones (134/192, 70%) , most likely due to the lack of an internal promoter in the IRES-␤-geo cassette. As expected, not reveal cells expressing the ␤-geo marker. Homozygous K-ras V12/V12 embryos die at midgestation with a phenotype similar all G418 resistant clones were positive for X-Gal staining (data not shown). Two clones (MCG224 and MCG231) were selected to that described for K-ras Ϫ/Ϫ mice (Johnson et al., 1997) , indicating that the knocked in transcriptional STOP sequences ef-for a second recombination event in the 5Ј end of the same K-ras allele. This targeting event allowed us to replace the endogenous fectively prevent expression of the K-ras V12 allele.
expression, presumably due to partial excision of the floxed STOP transcriptional sequences. Thus, we treated K-ras ϩ/V12 ; CMV-Cre ϩ/T MEFs with G418 for five days to eliminate those cells not expressing K-ras V12 transcripts. In addition, we generated MEFs in which the K-ras V12 allele is transcriptionally activated in vitro. To this end, we crossed K-ras ϩ/V12 animals with RERTn mice (Figure 3 ), a knockin strain that expresses the inducible Cre-ERT2 recombinase (Brocard et al., 1997) under the control of the locus encoding the large subunit of RNA polymerase II (V.C., N.M., C.G., and M.B., unpublished data). We treated the resulting K-ras ϩ/V12 ;RERTn ϩ/ERT MEFs for six days with 4-hydroxy-tamoxifen (4-OHT) to activate the inducible Cre-ERT2 recombinase and with G418 for five additional days to select for ␤-geo ϩ cells. The resulting K-ras ϩ/V12 ; RERTn ϩ/ERTOHT MEFs uniformly express the ␤-geo marker.
MEFs that only express the wild-type K-ras allele, including K-ras ϩ/V12 , K-ras ϩ/ϩ ;CMV-Cre ϩ/T and K-ras ϩ/V12 ;RERTn ϩ/ERT MEFs, undergo crisis, also known as proliferative senescence, after few passages in culture ( Figure 4A ). Upon continuous passage, these MEFs become immortal following the same kinetics as K-ras ϩ/ϩ MEFs. In contrast, MEFs expressing the oncogenic K-ras ϩ/V12 allele, including K-ras ϩ/V12 ;CMV-Cre ϩ/T and K-ras ϩ/V12 ; RERTn ϩ/ERTOHT MEFs, do not undergo proliferative senescence and proliferate continuously as immortal cells ( Figure 4A ).
Signaling pathways
Proliferating primary K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs contain lower steady-state levels of phosphorylated Erk1/2 proteins than control K-ras ϩ/ϩ or K-ras ϩ/V12 MEFs. However, these MEFs exhibit a similar Erk1/2 phosphorylation response upon EGF treatment ( Figure 4B ). On the other hand, serum-starved primary K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs display a more sustained Erk1/2 phosphorylation in response to EGF than control MEFs ( Figure  4C ). Sustained activation of the Erk pathway has been associated with cell cycle arrest (Marshall 1995; Agell et al., 2002) . However, transient activation of Erk is not sufficient to induce proliferation (Balmanno and Cook, 1999) . Moreover, activation of Erk by a constitutively active MAP kinase kinase (Mek1) induces differentiation of PC12 cells but transformation of NIH3T3 cells (Cowley , 1994) . Thus, the precise levels and duration of Erk1/2 phosphorylation required to elicit specific cellular responses A: Schematic representation of the RT-PCR strategy used to identify transcripts from (WT) wild-type K-ras and (V12) oncogenic K-ras V12 alleles. White may vary in different cell types. Our results suggest that the susboxes, K-ras transcripts. Numbers indicate exons. Gray box, IRES-␤-geo setained activation of Erk1/2 induced by the endogenous K-ras V12 quences present in K-ras V12 transcripts. Translational initiator (ATG) and termioncogene may be at least partially responsible for the observed nator (TGA) codons, (pA) polyadenosine tail, (V12) oncogenic mutation, loss of proliferative senescence of K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs. and sizes of the RT-PCR products before and after SfcI (S) digestion are indicated.
We also observed prolonged activation of downstream ki-B: RT-PCR analysis of transcripts present in K-ras ϩ/ϩ MEFs, K-ras ϩ/V12 ; nases in the ras survival pathway. As illustrated in Figure 4C for at least one hour, whereas in control MEFs, phosphorylated Akt can no longer be detected 10 min after EGF exposure. Sustained Akt activation may also contribute to loss of proliferative senescence of K-ras V12 -expressing MEFs. Expression of an endogenous K-ras V12 oncogene prevents proliferative senescence K-ras V12 -expressing MEFs senesce upon We have followed two independent strategies to generate MEFs oncogenic stress expressing the oncogenic K-ras V12 allele. First, we obtained Previous studies have indicated that primary MEFs enter a se-MEFs from E13.5 embryos derived from crosses between nescence state upon oncogenic stress induced by ectopic ex-K-ras ϩ/V12 and CMV-Cre ϩ/T mice (Figure 3 ). CMV-Cre ϩ/T is a transpression of ras oncogenes (Serrano et al., 1997) . These senesgenic strain that express the Cre recombinase under the control cent cells display permanent G1 arrest and are phenotypically of the CMV viral promoter (Schwenk et al., 1995) . All E13.5 K-ras ϩ/V12 ;CMV-Cre ϩ/T embryos analyzed were mosaic for ␤-geo indistinguishable from those undergoing proliferative senes- Black boxes, K-ras coding sequences; white boxes, K-ras noncoding sequences; Hyg, PGK-Hygromycin cassette; STOP, transcriptional inhibitory sequences; IRESgeo, IRES-␤-geo cassette; pA, polyadenylation signal. Triangle, loxP sites. V12, oncogenic mutation in codon 12 that results in replacement of a glycine residue by valine. Arrow, active K-ras transcription; X, impaired K-ras transcription.
cence. Since MEFs expressing the K-ras V12 allele do not undergo sor proteins encoded by this locus. Likewise, these immortal K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs retain a normal P53 pathway as proliferative senescence ( Figure 4A ), we investigated whether this property could be due to loss of their senescence program.
determined by their ability to respond to genotoxic damage. As illustrated in Figure 5D , doxorubicin treatment of passage 25 To this end, primary K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs were infected with retroviruses carrying H-ras, K-ras4A, or K-ras4B onco-K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs results in the efficient induction of both P53 and P21Cip expression ( Figure 5D ). These results genes. As illustrated in Figure 5A , these MEFs undergo senescence due to oncogenic stress even if they have overriden prolif-suggest that immortalization of MEFs expressing an endogenous K-ras V12 oncogene does not involve loss of tumor suppres-erative senescence. Activation of the senescence program was monitored by expression of their endogenous ␤-galactosidase sor pathways frequently found responsible for the immortalization of normal MEFs in culture. (data not shown) and overexpression of Ris1, the product of the ras-induced senescence gene, m-ris1 ( Figure 5B ) (Barradas To investigate whether MEFs expressing the K-ras V12 oncogene contain other type of mutations such as chromosomal et al., 2002) . These observations indicate that immortalization induced by the endogenous K-ras V12 oncogene does not prevent abnormalities, we performed spectral karyotyping analysis (SKY) of primary and late passage (p19) MEFs. Less than 5% of senescence induced by oncogenic stress. These findings suggest that proliferative senescence and senescence induced by primary K-ras ϩ/ϩ ;CMV-Cre ϩ/T and K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs display chromosomal abnormalities despite the presence of oncogenic stress involve different mechanisms.
the CMV-Cre transgene (Loonstra et al., 2001) . However, as K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs proliferate in culture, the number Transformation of primary MEFs expressing an endogenous K-ras V12 oncogene of chromosomal abnormalities increases substantially, reaching up to 50% of the observed metaphases by passage 19. Abnor-K-ras ϩ/V12 ;CMV-Cre ϩ/T and K-ras ϩ/V12 ;RERTn ϩ/ERTOHT MEFs show loss of contact inhibition, but do not display the typical morphol-malities include tetraploidity, reciprocal and unbalanced translocations, deletions, acentric fragments, and dicentric fusions. ogy of transformed cells. Moreover, they do not grow in semisolid media and do not form tumors when injected into immuno-Parallel cultures of immortal (passage 19) K-ras ϩ/ϩ ;CMV-Cre ϩ/T MEFs only display tetraploid cells in 15% of the metaphases compromised mice (data not shown). These MEFs are also resistant to transformation by nuclear oncogenes such as ade-analyzed. These results suggest that immortalization induced by expression of the oncogenic K-ras V12 allele may induce dereg-novirus E1A (Ruley, 1983) ( Figure 5C ). However, K-ras ϩ/V12 ; CMV-Cre ϩ/T MEFs undergo morphologic transformation upon ulation of checkpoints responsible for maintaining chromosomal stability, thus contributing to tumor development. cotransfection with exogenous K-ras and adenoviral E1A oncogenes with efficiencies similar to that of wild-type MEFs ( Figure  5C ). Transformed K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs induce tumors Tumor development in K-ras ؉/V12 mice Crosses between K-ras ϩ/V12 and CMV-Cre ϩ/T transgenic mice when injected in nude mice with an efficiency similar to wildtype transformed MEFs (data not shown). These results indicate result in frequent embryonic lethality, presumably due to expression of the K-ras V12 oncogene during early development (un-that transformation of primary rodent cells requires the cooperation of two oncogenes, providing that they are expressed at published data). However, a significant number of K-ras ϩ/V12 ; CMV-Cre ϩ/T mice reach adulthood. These mice develop breath-high levels.
ing difficulties after seven to eight months of age ( Figure 6 , top panel). Postmortem examination reveals a broad spectrum of Chromosomal abnormalities in late passage K-ras V12 -expressing MEFs multifocal lesions in lungs, ranging from small patches of bronchiolo-alveolar hyperplasias to large bronchiolo-alveolar adeno-Overcoming proliferative senescence often involves mutations in either the INK4a or P53 loci. Late passage (p25) K-ras ϩ/V12 ; mas and adenocarcinomas that compress adjacent lung structures ( Figures 6A-6D ). These tumor cells express surfactant CMV-Cre ϩ/T MEFs retain a functional INK4a locus, at least as determined by the normal levels of expression of both P16INK4a protein C (SPC), suggesting that they are derived from type II pneumocytes ( Figure 6E ). Very occasionally, CC10 immuno-(not shown) and P19Arf (Figure 5D ), the two tumor suppres-mutant mice, such as pituitary adenomas or hemangiosarcomas (Sotillo et al., 2001) , thus suggesting that K-Ras V12 signaling in these cells does not contribute to their tumorigenic phenotype (see below). K-ras ϩ/V12 ;CMV-Cre ϩ/T ;cdk4 ϩ/R24C mice display focal metaplasia in pancreatic ducts not observed in either parental strain. This metaplasia consists of tall columnar cells with abundant apical mucin, resembling gastric surface epithelial cells (Figure 7) . This abnormality closely resembles human mucinous metaplasia (Chen et al., 1985) , a preneoplastic lesion that often contains K-ras oncogenes (Yanagisawa et al., 1993) .
Controlled activation of the oncogene K-ras V12 allele in postnatal mice
To activate expression of the K-ras V12 allele in somatic cells in a temporally controlled manner, we submitted P10 K-ras ϩ/V12 ; RERTn ϩ/ERT mice to systemic treatment involving limiting doses of 4-OHT (0.1 mg, 3 times a week for 2 weeks). Exposure to this synthetic steroid results in the activation of the inducible Cre-ERT2 recombinase leading to removal of the STOP transcriptional sequences that prevent expression of the targeted K-ras V12 allele. X-Gal analysis of tissue sections two weeks after 4-OHT treatment revealed that 5% to 15% of cells in most tissues expressed the ␤-geo marker (data not shown). After seven months of age ( Figure 6 , top panel), all treated mice (n ϭ 9) developed breathing difficulties due to the presence of multiple lesions in the lung, indistinguishable from those described above. Southern blot analysis of DNA isolated from lung adenomas reveals that these benign tumors maintain the wild- Histological examination of other tissues obtained from K-ras ϩ/ϩ , K-ras ϩ/V12 , and K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs either not treated (Ϫ) or these mice reveals a similar percentage of ␤-geo ϩ cells (5% to treated (ϩ) with 50 ng/ml of EGF for 5 min. 15%) as in young mice immediately after 4OHT treatment. These C: Kinetic analysis of the activation of Erk1/2 and Akt kinases upon addition of EGF (50 ng/ml) to serum-starved primary K-ras ϩ/ϩ ;CMV-Cre ϩ/T and observations suggest that most cells expressing the oncogenic K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs. Total Erk1/2 or Akt proteins serve as loading K-ras V12 allele do not have proliferative advantage. Indeed, a controls. significant number of morphologically normal ␤-geo ϩ cells, indicative of K-ras V12 expression, could be identified in the bronchiolo-alveolar lung epithelia ( Figure 8A ). In other tissues, ␤-geo ϩ cells appear morphologically normal and within areas comstaining revealed a few cells of Clara cell origin ( Figure 6F ). pletely devoid of any hyperplastic growth ( Figures 8B-8H) . These results are similar to those recently reported in other These tissues include testicular seminiferous tubes ( Figure 8B ), animal models expressing K-ras oncogenes (Jackson et al., epithelial cells of the renal Bowman's capsules ( Figure 8C) , hair 2001; Johnson et al., 2001; Meuwissen et al., 2001) . We have follicles in the dermis (some of these being completely made also observed occasional foci of hyperplastic epithelial cells in up of ␤-geo ϩ cells) ( Figure 8D ), the molecular layer of the cerenonrespiratory bronchioles (data not shown). Tumors other than bellum ( Figure 8E ), and liver hepatocytes ( Figure 8F ). Of particulung adenomas also appear in these mice, including histiocytic lar interest is the presence of morphologically normal ␤-geo ϩ sarcomas (2/20), anal papillomas (3/20), and sarcomas (3/20). cells in the exocrine pancreas ( Figure 8G ), since most human All tumors and hyperplastic regions invariably express the ␤-geo pancreatic adenocarcinomas contain K-ras oncogenes (Almomarker ( Figures 6A and 6B) . Expression of the targeted K-ras V12 guera et al., 1988). Moreover, these mice contain a significant allele was confirmed by RT-PCR analysis in selected samples number of intestinal crypts entirely formed by ␤-geo ϩ cells (Fig-(Figure 2B ). ure 8H), suggesting that activation of the K-ras V12 oncogene has We crossed K-ras ϩ/V12 ;CMV-Cre ϩ/T mice with cdk4 R24C/R24C occurred in stem cells that retain their full potential to form these knockin animals (Sotillo et al., 2001) . K-ras ϩ/V12 ;CMV-Cre ϩ/T ; crypts. These observations indicate that endogenous K-ras V12 cdk4 ϩ/R24C mice develop multifocal lung adenomas with signifiexpression does not perturb the proliferation and/or differentiacantly shorter latency ( Figure 6, top panel) . These mice also tion programs of most cell types. develop histiocytic sarcomas, anal papillomas, and sarcomas.
We observed similar results in K-ras ϩ/V12 ;CMV-Cre ϩ/T mice However, the presence of the activated K-ras V12 allele does not as well as in double mutant K-ras ϩ/V12 ;CMV-Cre ϩ/T ;cdk4 ϩ/R24C animals (data not shown). These observations indicate that ex-accelerate the development of tumors characteristic of cdk4 R24C pression at physiological levels of even two distinct oncogenic EGF treatment, K-ras V12 -expressing MEFs display a more sustained signaling response than control MEFs in their down-proteins acting in convergent pathways is not sufficient to induce unscheduled proliferation in most cell types. stream mitogenic (Raf/Mek/Erk) and survival (PI3K/Pdk/Akt) pathways than control MEFs, a trait likely to contribute to their immortal properties. However, expression of the oncogenic Discussion K-ras V12 allele at physiological levels is not sufficient to induce morphologic transformation in vitro or tumorigenic properties Expression of ras oncogenes under the control of retroviral or in vivo, even in the presence of a cooperating oncogene such other highly active promoters in primary MEFs leads to G1 arrest as E1A. Thus, it is likely that if expressed at physiological levels, and premature senescence due to oncogenic stress (Serrano et al., 1997) . Based on these observations, it was proposed that even rodent MEFs may need multiple mutations to acquire neoplastic properties. transformation by ras oncogenes requires abrogation of cellular senescence programs, for instance by mutation of the P53 or Several in vivo models expressing K-ras oncogenes have been recently described (Fisher et al., 2001; Jackson et al., INK4a tumor suppressor pathways. Here, we show that expression of a targeted K-ras V12 oncogene under the control of its 2001; Johnson et al., 2001; Meuwissen et al., 2001) . One of these (Johnson et al., 2001) recapitulates more closely human own promoter does not induce senescence, but rather hyperproliferative properties characteristic of immortal cells. Upon disease since it involves occasional activation of an endogenous that described by Jackson et al. (2001) in which transcription of the targeted K-ras allele requires expression of Cre recombinase. In our model, we have activated the K-ras V12 allele by introducing either a CMV-Cre transgene that is expressed throughout development or a knocked in inducible Cre-ERT2 recombinase that can be activated at any time in any cell type by exposure to 4-OHT (V.C., N.M., C.G., and M.B., unpublished data). In addition, our targeting strategy allows easy monitoring of those cells expressing the targeted K-ras V12 oncogene by staining for a marker protein (␤-geo) expressed from the same K-ras V12 transcript by a bicistronic strategy. K-ras ϩ/V12 mice carrying a CMV-Cre transgene develop lung adenomas and adenocarcinomas with complete penetrance. About one-third of the animals also develop additional tumors. In contrast, when the targeted K-ras V12 allele is activated postnatally for a short period of time (2 weeks), we observe multifocal lung adenomas and adenocarcinomas, but, so far, no other tumor types. The main difference between these models is that whereas intragenic recombination (Johnson et al., 2001) or CMV-Cre-dependent activation (this work) may occur at any time throughout embryonic or postnatal development, 4-OHTmediated activation of K-ras V12 only takes place for a short period of time. These observations suggest that tumor development induced by endogenous K-ras oncogenes is highly dependent not only on the cell type, but also on their developmental and/ or differentiation state when activation occurs.
The inclusion of a marker protein in the knock in strategy has allowed us to establish that expression of the targeted K-ras V12 allele is not limited to those cells that undergo hyperplastic growth or tumor development. On the contrary, K-ras ϩ/V12 ; CMV-Cre ϩ/T and 4-OHT-treated K-ras ϩ/V12 ;RERTn ϩ/ERT mice express the oncogenic K-ras V12 allele in a wide range of cell types. However, most of these cells do not display altered morphologies or hyperplastic properties. Examination of young K-ras ϩ/V12 ; CMV-Cre ϩ/T or K-ras ϩ/V12 ;RERTn ϩ/ERT mice immediately after 4-OHT treatment reveals a similar percentage of ␤-geo ϩ cells in lungs as in other tissues in which no tumor development occurs, even after eight months of life. Thus, the high suscepti- CMV-Cre ϩ/T ;cdk4 ϩ/R24C (black circle), and 4-OHT treated K-ras ϩ/V12 ;RERTn ϩ/ERT Whether this is due to a failure of the K-ras V12 oncogene to elicit (black triangle) mice. a mitogenic response or to activation of inhibitory pathways in Lower panel: Bronchiolo-alveolar tumors in K-ras ϩ/V12 ;CMV-Cre ϩ/T mice.
these cells remains to be explored. suggest that activation of K-ras onogenes is not the primary and a nonrespiratory bronchiole (white arrow). event in the development of human colon carcinomas (Oudejans et al., 1991) . Remarkably, tissues of double mutant K-ras ϩ/V12 ; CMV-Cre ϩ/T ;cdk4 ϩ/R24C mice also contain a significant percentage of K-ras V12 -expressing cells. These cells also contain a mu-K-ras oncogene by intragenic recombination in somatic cells.
tant Cdk4 R24C kinase whose activity cannot be downregulated These mice develop lung adenocarcinomas with complete penby INK4 inhibitors. However, none of these tissues display abetrance. Approximately one-third of these mice also develop normal morphology or hyperproliferative properties, indicating thymic lymphomas and skin papillomas, as well as aberrant that most cell types tolerate a significant level of oncogenic intestinal crypt foci, but no colon tumors. However, this model burden without neoplastic consequences. On the other hand, does not allow identification of those cells expressing the K-ras coexpression of the mutant Cdk4 R24C protein in bronchiolo-alveoncogenes or the timing in which K-ras activation occurs, thus olar cells susceptible to transformation by K-ras V12 significantly making it difficult to study the early stages of the disease.
In this study, we have used a targeting strategy similar to reduces tumor latency. DNA that encompasses the mouse 3ЈUTR and a 400 bp SacI-StuI fragment
Our results strongly suggest that tumor susceptibility deof pCMV-K-ras DNA that contains the human noncoding exon 0 (Leon et pends to a great extent upon cellular context. Unveiling those al., 1987) . To target the 3Ј region of the K-ras locus, we generated a targeting pathways responsible for the dramatic differences in the re- TGA stop codon and 552 bp upstream from a putative polyadenylation site likely to correspond to the 2 Kb K-ras transcript (Leon et al., 1987) . To target Experimental procedures the 5Ј region of the K-ras locus, we mutagenized two nucleotides (underlined) corresponding to codon 12 (GGT [Gly] to GTA [Val] ) in a plasmid containing Targeting vectors the first K-ras exon within a 700 bp EcoRI DNA fragment. These mutations K-ras genomic DNA clones were isolated from a 129/Sv genomic DNA library also create a diagnostic SfcI restriction site, CTGTAG. Selected clones were sequenced to ensure that only the desired mutations were introduced. To (Stratagene) using as probes a 600 bp EcoRI-HindIII fragment of pSK-K-ras generate the targeting vector (pMCG25), we inserted a PGK-Hyg-STOP oncogenes and selected in the presence of 2 g/ml of puromycin for 3 days (Serrano et al., 1997) . For transformation assays, we transfected primary cassette flanked by loxP sites within a 5 Kb NotI-EcoRV DNA fragment at MEFs (passage 3) by the standard calcium chloride protocol with pMCVan EcoRI site located 100 bp upstream of the mutagenized exon 1. This E1A12S (Kraus et al., 1992) and pBABE-puro-K-rasA V12 or pBABE-purocassette had been previously generated by inserting a 1.8 Kb BglII DNA K-rasB V12 DNAs. We scored foci of morphologically transformed cells after fragment containing the hygromycin resistance gene (Hyg) under the control 20 days in culture. For tumorigenesis assays, foci were inoculated in the of the phosphoglycerolkinase (PGK) promoter (a gift of Dr. I. Sanchez-García) flank of nude mice (10 6 cells per flank). Mice were sacrificed when tumors into the BglII site of pBS302 (Gibco-BRL), a plasmid that contains the floxed reached a diameter of 1 cm. STOP sequences.
Western blot analysis Generation of knockin mice
Tissue samples or cultured cells were lysed in 50 mM Tris-HCl (pH 7.4) R1 ES cells (Nagy et al., 1993) were cultured in Dulbecco's modified Eagle's containing 150 mM NaCl, 0.5% NP-40, and protease inhibitors. Extracts medium (DMEM) supplemented with 15% heat inactivated fetal bovine serum were separated by 12% or 15% SDS-PAGE, transferred to nitrocellulose (FBS) and 10 3 U/ml of leukemia inhibitory factor (LIF). 20 g of linearized filters, and incubated with the corresponding antibodies including anti-Erk pMCG26 DNA were electroporated into 5.6 ϫ 10 6 R1 cells in 0.8 ml at 240 (sc-94, Santa Cruz Biotechnology), anti-P-Erk, anti-P-Akt, anti-Akt (9019S, V and 500 F with a Genepulser (BioRad). Cells were grown for 7 days in 9271S, 9272, respectively, New England Biolabs), anti-Ris1, anti P19Arf 200 g/ml of G418 (Sigma). G418-resistant clones were submitted to South-(ab80, Abecam), anti-P53 (Ab3, Oncogene Research Products), anti-P21Cip ern blot analysis to identify those that had undergone the expected recombi-(sc-397G, Santa Cruz Biotechnology), and ␤-actin (AC-15, Sigma). Antibodnation event. Two clones (MCG224 and MCG231) were selected to target ies were detected with the appropriate horseradish peroxidase-linked secthe 5Ј region. To this end, 20 g of linearized pMCG25 DNA was electroporondary antibody and visualized with enhanced chemioluminiscent (ECL) ated as described above. Cells were grown for 7 days in 200 g/ml hygrosystem (Amersham). mycin and 2 M gancyclovir. DNA was isolated from double resistant clones and submitted to Southern blot analysis.
Spectral karyotyping (SKY) Targeted ES cells carrying the two recombination events in the same
Painting probes for each chromosome were generated from flow-sorted allele were identified by X-Gal staining only after transfection with a plasmid mouse chromosomes using sequence-independent DNA amplification. Laencoding a Cre recombinase. Positive clones were submitted to cytogenetic beling was performed by incorporating four different dyes in a combination analysis and two of them (MCG537 and MCG758) among those exhibiting sequence that allows unique and differential identification of each chromoa normal karyotype were used to generate chimeric mice by microinjection some. To obtain mouse metaphases, MEF cultures were exposed to colinto C57BL/6 blastocysts. Chimeric male mice were backcrossed to cemid for 3 hr, treated for 20 min in isotonic conditions (70 mM KCl), washed C57BL/6 females and germline transmission of the targeted allele scored three times in Carnoy's fixative (methanol:acetic acid, 3:1), and dropped into by Southern blot analysis of tail DNA from the agouti offspring. glass slides. Prior to hybridization, chromosome spreads were treated with pepsin (0.001% pepsin in 10 mM HCl, 37ЊC). A mouse SKY probe mixture PCR genotyping (Applied Spectral Imaging) was hybridized for 48 hr. Washing of preparations For routine genotyping of K-ras ϩ/V12 mice, we submitted tail DNA to PCR and detection of probe was carried out according to the instructions of the analysis at 94ЊC for 5 min, followed by 30 cycles of 94ЊC denaturing for 1 manufacturer. Chromosome spreads were counterstained with DAPI. Image acquisition was performed with the SpectraCube system (Applied Spectral min, 60ЊC annealing for 1 min, and 72ЊC extension for 1 min, followed by Imaging) mounted on an Axioplan 2 microscope (Zeiss). an elongation cycle of 72ЊC for 10 min with the following primers: 5Ј forward primer (5I0, 5Ј-AGGGTAGGTGTTGGGATAGC-3Ј), reverse wild-type primer Histological analysis, X-Gal staining, and immunohistochemistry (3Ex1, 5Ј-CTCAGTCATTTTCAGCAGGC-3Ј), and reverse mutant primer Mice were sacrificed at the specified times or upon onset of visible disease. (103rev-2, 5Ј-CTGCTCTTTACTGAAGGCTC-3Ј). The sizes of the diagnostic Tissue samples were fixed in 10% formalin and processed for hematoxylin PCR products are 403 bp for the wild-type allele and 621 bp for the targeted and eosin (H&E) staining. X-Gal staining was performed as described (Hogan K-ras allele. In tissues and MEFs in which the floxed STOP cassette present et al., 1994) . Counterstaining of paraffin sections was performed with nuclear in the targeted K-ras allele has been excised, primers 5I0 and 3Ex1 yield a fast red. Antibodies against SP-C (AB3786, Chemicon) and CC10 (sc-9772, DNA fragment of 669 bp. Santa Cruz Biotechnology) were used at a final dilution of 1:500.
RT-PCR analysis Acknowledgments
To monitor expression of the K-ras V12 allele, we isolated RNA form 10 6 K-ras ϩ/V12 ;CMV-Cre ϩ/T (␤-geo ϩ cells) and K-ras ϩ/V12 (␤-geo Ϫ cells) MEFs using
We thank M. San Romá n, R. Villar, R. Gonzá lez, I. Segovia, M. Muñ oz, and TRIzol reagent (Gibco-BRL) and performed RT-PCR analysis using primers M. Turmo for excellent technical assistance. We also thank C. Gó mez, M. specific for the first and third K-ras exons. First strand cDNA was generated Riffo, S. Ortega (Transgenic Unit, CNIO), and K. Vintersten (Transgenic Unit, using the GeneAmp RNA PCR Kit (Applied Biosystems). PCR was performed EMBL) for their invaluable help in generating ES cells and chimeric mice, using a forward primer (5Ј-ACGGAATCCCGTAACTC-3Ј) derived from exon 1 J.F. García for advice with pathology examinations, A.M. Alvarez for help sequences and a reverse primer (5Ј-CCTTGCTAACTCCTGAGCC-3Ј) derived with FDG sorting, J.C. Cigudosa for the SKY studies, I Sanchez-García from exon 3 sequences. Conditions for PCR amplification were 94ЊC for 5 for the PGK-Hygro cassette, and M. Malumbres for critically reading the min., followed by 35 cycles of 94ЊC for 1 min, 60ЊC for 1 min, and 72ЊC for manuscript. We also thank the Immunohistochemistry and Animal Facility 1 min, followed by an elongation cycle of 72ЊC for 7 min. PCR products were Units of the CNIO for their support. The early phases of this work were digested for 1 hr at 37ЊC with SfcI and analyzed in 10% polyacrilamide gels.
carried out at the Centro Nacional de Biotecnología (CSIC), Madrid. This To separate ␤-geo ϩ and ␤-geo Ϫ cells, we mechanically disaggregated work was supported by grants from the V Framework Programme of the EU fresh tissues with a Medimachine (DakoCytomation), submitted to the C12-(to M.B. and M.S.), Ministerio de Ciencia y Tecnología (to M.B.), Ministerio FDG (Molecular Probes) protocol (Plovins et al., 1994) and sorted (MoFlo de Sanidad y Consumo and Comunidad Autó noma de Madrid (to C.G.), and system, DakoCytomation). Total RNA was purified from 2 ϫ 10 6 ␤-geo ϩ and Ligue contre le Cancer (Comité de Dordogne) and INSERM (to P.D.). N.M. ␤-geo Ϫ sorted cells using TRIzol reagent (Gibco-BRL) and submitted to RTwas supported by a Beca de Formació n para la Investigació n (BEFI, Fondo PCR analysis as indicated above.
de Investigació n Sanitaria) and A.D. by a fellowship from the Programa de Formació n de Personal Investigador (FPI, Ministerio de Ciencia y Tecnología).
Cell culture assays
We isolated and propagated MEFs from E13.5 embryos using a classical 3T3 protocol (Todaro and Green, 1963) . K-ras ϩ/V12 ;CMV-Cre ϩ/T MEFs were treated with 200 g/ml of G418 for five days. K-ras ϩ/V12 ;RERTn ϩ/ERT MEFs
